X
[{"orgOrder":0,"company":"Techdow USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Techdow USA Announces FDA Approval of Generic Lovenox\u00ae, (Enoxaparin Sodium \u2013 Preservative Free) In Prefilled Syringes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Techdow USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Techdow USA Announces Launch of its Generic Lovenox, (Enoxaparin Sodium \u2013 Preservative Free) in Prefilled Syringes","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV"},{"orgOrder":0,"company":"Techdow USA","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Techdow USA and CTTQ Pharma Announce Collaboration Agreement and Launch of Fosaprepitant for Injection","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase IV"}]
Find Clinical Drug Pipeline Developments & Deals by Techdow USA
Filters
Companies By Therapeutic Area
Details:
Under the agreement, CTTQ will manufacture Fosaprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, for Injection, the therapeutic generic equivalent of Emend, and will be sold under the Techdow USA Label.
Lead Product(s):
Fosaprepitant
Therapeutic Area: Gastroenterology
Product Name: Emend-Generic
Highest Development Status: Phase IV
Product Type: Small molecule
Recipient:
Chia Tai Tianqing Pharmaceutical Group
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
August 22, 2023
Details:
Lovenox-Generic (enoxaparin sodium) is a Factor XI/XIa inhibitor with a Prefilled Syringes with 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg strengths low molecular weight heparin (LMWH), is an anticoagulant that helps to prevent thrombosis.
Lead Product(s):
Enoxaparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Lovenox-Generic
Highest Development Status: Phase IV
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 08, 2023
Details:
Enoxaparin sodium binds to antithrombin III, a serine protease inhibitor, forming a complex that irreversibly inactivates factor Xa, which is frequently used to monitor anticoagulation in the clinical setting.
Lead Product(s):
Enoxaparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Lovenox-Generic
Highest Development Status: Phase IV
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 20, 2023